Riskpilot← Back to searchSign inGet full accessDEFENSIN THERAPEUTICS ApS
APSActiveCVR 35513280Rigensgade 11A, 2.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20131 employeeswww.defensintherapeutics.com
Revenue 2024
—
EBITDA margin
—
+2% vs 2023
Equity ratio
97.1%
Financial strength
Net profit 2024
DKK -131K
+69% vs 2023
| Revenue | — | — |
| EBITDA | DKK -413K | +2% |
| Net profit | DKK -131K | +69% |
| Total assets | DKK 1,4M | -4% |
| Equity | DKK 1,3M | -5% |
| Employees | 1 | — |
Legal name
DEFENSIN THERAPEUTICS ApS
CVR number
35513280
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. oktober 2013
Share capital
DKK 1.422.481
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af bestyrelsens formand og en direktør.
Company purpose
Selskabets formål er at drive forskning og udvikling rettet mod udvikling af medicinske produkter, som kan regulere microbiota og dermed relaterede sygdomme, og andre hermed relaterede aktiviteter.
Address
Rigensgade 11A, 2.
Phone
+4525471646
Email
pno@defensintherapeutics.com
Website
www.defensintherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 11.143 | 0 | — | — | — | 0 | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -626 | -831 | 7.421 | -2.287 | -3.259 | -1.834 | -2.301 | -343 | -470 | -421 | -413 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -626 | -831 | 7.421 | -2.287 | -3.259 | -1.834 | -2.301 | -343 | -470 | -421 | -413 |
| Net financials | -2 | -1 | -55 | -31 | -16 | -19 | -23 | -27 | -19 | -4 | -4 |
| Profit before tax | -628 | -832 | 7.366 | -2.318 | -3.275 | -1.853 | -2.325 | -370 | -489 | -425 | -417 |
| Tax | -8 | -21 | 1.338 | -285 | -322 | -132 | -9 | -5 | -15 | -0 | -287 |
| Net profit | -620 | -811 | 6.028 | -2.033 | -2.953 | -1.721 | -2.316 | -366 | -474 | -425 | -131 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 511 | 242 | 7.744 | 4.123 | 1.121 | 5.042 | 2.699 | 2.180 | 1.765 | 1.410 | 1.352 |
| Equity | 377 | -53 | 5.975 | 3.942 | 1.030 | 4.823 | 2.508 | 2.142 | 1.668 | 1.380 | 1.313 |
| Long-term debt | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 134 | 296 | 1.769 | 181 | 91 | 219 | 191 | 38 | 97 | 30 | 39 |
| Total debt | 134 | 296 | 1.766 | 181 | 91 | 219 | 191 | 38 | 97 | 30 | 39 |
EBITDA margin
-41314400.0%
This company
15.8%
Market median
-261483644% vs market
20142024
Equity ratio
97.1%
This company
38.2%
Market median
+154% vs market
20142024
Return on equity
-9.9%
This company
18.4%
Market median
-154% vs market
20142024
Net profit margin
-13053400.0%
This company
8.1%
Market median
-161153186% vs market
20142024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20142024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2013-10-06 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PH Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PN INVESTMENT ApS | Company | 33.3% | 33.3% | 2015 |
NEVE INVEST ApS | Company | 15.0% | 15.0% | 2015 |
NOVOZYMES A/S | Company | 15.0% | 15.0% | 2015 |
| Individual | 15.0% | 15.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
DEFENSIN THERAPEUTICS ApS Board members of DEFENSIN THERAPEUTICS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Hviid Nordkild | Chief Executive Officer | 0 companies |
| Ejner Bech Jensen | Chairman | 0 companies |
| Jan Wehkamp | Board of Directors | 0 companies |
| Matthew Alister Cooper | Board of Directors | 0 companies |
| Søren Neve | Board of Directors | 0 companies |
| Robert Ehehalt | Board of Directors | 0 companies |